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Abstract 
Diabetes mellitus is associated with deterioration of glycemic control and progressive met-
abolic derangements. This study investigated the effect of honey as an adjunct to glibenclamide 
or metformin on glycemic control in streptozotocin-induced diabetic rats. Diabetes was 
induced in rats by streptozotocin. The diabetic rats were randomized into six groups and 
administered distilled water, honey, glibenclamide, glibenclamide and honey, metformin or 
metformin and honey. The animals were treated orally once daily for four weeks. The diabetic 
control rats showed hypoinsulinemia (0.27 ± 0.01 ng/ml), hyperglycemia (22.4 ± 1.0 mmol/L) 
and increased fructosamine (360.0 ± 15.6 µmol/L). Honey significantly increased insulin (0.41 
± 0.06 ng/ml), decreased hyperglycemia (12.3 ± 3.1 mmol/L) and fructosamine (304.5 ± 10.1 
µmol/L). Although glibenclamide or metformin alone significantly (p < 0.05) reduced hyper-
glycemia, glibenclamide or metformin combined with honey produced significantly much 
lower blood glucose (8.8 ± 2.9 or 9.9 ± 3.3 mmol/L, respectively) compared to glibenclamide 
or metformin alone (13.9 ± 3.4 or 13.2 ± 2.9 mmol/L, respectively). Similarly, glibenclamide or 
metformin combined with honey produced significantly (p < 0.05) lower fructosamine levels 
(301.3 ± 19.5 or 285.8 ± 22.6 µmol/L, respectively) whereas glibenclamide or metformin alone 
did not decrease fructosamine (330.0 ± 29.9 or 314.6 ± 17.9 µmol/L, respectively). Besides, 
these drugs or their combination with honey increased insulin levels.  Glibenclamide or 
metformin combined with honey also significantly reduced the elevated levels of creatinine, 
bilirubin, triglycerides, and VLDL cholesterol.  These results indicate that combination of 
glibenclamide or metformin with honey improves glycemic control, and provides additional 
metabolic benefits, not achieved with either glibenclamide or metformin alone. 
Key  words:  Diabetes  mellitus;  streptozotocin;  fructosamine;  glibenclamide;  metformin;  tualang 
honey 
Introduction 
An  intensive  treatment  of  hyperglycemia  is 
known to lower the risks of microvascular complica-
tions such as retinopathy, nephropathy, and neurop-
athy as well as the incidence of cardiovascular events Int. J. Biol. Sci. 2011, 7 
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in both type 1 and type 2 diabetic patients [1, 2]. Un-
fortunately,  many  diabetics  hardly  achieve  and/or 
maintain the recommended 7% glycated hemoglobin 
(HbA1c) goal for blood glucose control and are there-
fore exposed to increasing risks of diabetic complica-
tions as glycemic control deteriorates over time [3]. 
Studies have shown that diabetes mellitus is a pro-
gressive  disorder  which  cannot  be  effectively  man-
aged  with  drug  monotherapy  [4-5].  Regardless  of 
drug  management,  the  pancreatic  -cells  in  type  2 
diabetic  patients  continue  to  deteriorate  leading  to 
worsening glycemic control and consequent require-
ment for multiple therapies or exogenous insulin [6].  
Increased generation of reactive oxygen species 
(ROS) resulting from metabolism of excessive glucose 
and/or free fatty acid has been identified as a con-
tributor to the deterioration of pancreatic β-cell func-
tion [7, 8]. Due to the relatively low expression of an-
tioxidant  enzymes  such  as  superoxide  dismutase, 
catalase, and glutathione peroxidase in the pancreas 
[9], the pancreatic -cells may be highly vulnerable to 
damage when exposed to oxidative stress. Thus, oxi-
dative stress may play a major role in -cell deterio-
ration frequently observed in type 2 diabetes [10].  
Antioxidants  have  been  suggested  to  afford 
protection to the pancreas against oxidative stress in 
diabetes mellitus [11]. We had reported earlier that, in 
experimental rat models of diabetes mellitus, Malay-
sian tualang honey exhibited glucose lowering effect 
and  ameliorated  oxidative  stress  in  the  kidney  and 
pancreas [12, 13] and that protection of the pancreas 
against oxidative stress might contribute to its hypo-
glycemic effect. In the present study, we have inves-
tigated how the addition of tualang honey as an ad-
junct to glibenclamide or metformin affects glycemic 
control in streptozotocin-induced diabetic rats. 
Materials and Methods 
Animals 
The use of rats and all the experimental proce-
dures were approved by the Animal Ethics Commit-
tee of Universiti Sains Malaysia and were performed 
in accordance with the Institutional Guidelines for the 
Care and Use of Animals for Scientific Purposes and 
in accordance with the Recommendations from Hel-
sinki  Declaration.  A  total  of  sixty  male  Spra-
gue-Dawley  rats  aged  12-14  weeks  were  obtained 
from  the  Laboratory  Animal  Research  Unit  of  Uni-
versiti  Sains  Malaysia,  Health  Campus,  Kelantan, 
Malaysia. The animals were acclimatized to the ani-
mal room condition for at least a week at 25±20C with 
12-hour  light/12-hour  dark  cycles  prior  to  the  ex-
periment. All animals were supplied with commercial 
pellet food and water ad libitum. 
Preparation of tualang honey, glibenclamide and 
metformin  
Tualang honey (AgroMas®, Malaysia) was sup-
plied  by  Federal  Agricultural  Marketing  Authority 
(FAMA),  Kedah,  Malaysia.  This  honey  has  the  fol-
lowing  composition:  total  reducing  sugar  (67.5%) 
[fructose (29.6 %), glucose (30.0 %), maltose (7.9 %); 
fructose/glucose  ratio  (0.99)],  sucrose  (0.6  %)  and 
water (20.0 %). Tualang honey (1.0 g/kg body weight) 
was  freshly  diluted  with  distilled  water  just  before 
each administration. Glibenclamide (0.6 mg/kg body 
weight)  and  metformin  (100  mg/kg  body  weight) 
were  dissolved  in  dimethyl  sulfoxide  and  distilled 
water, respectively before they were administered. 
Induction of diabetes 
Diabetes was induced in overnight fasted rats by 
a single intraperitoneal injection of streptozotocin (60 
mg/kg body weight) in a 0.1M sodium citrate buffer 
(pH  4.5).  The  age-matched  control  rats  received  an 
equivalent amount of citrate buffer. Food and water 
intake  were  closely  monitored  daily  after  strepto-
zotocin  (STZ)  administration.  The  development  of 
hyperglycemia in rats was confirmed by fasting (16 
hour)  blood  glucose  measurement  in  the  tail  vein 
blood,  48  hours  after  STZ  administration,  with  a 
portable  glucometer  (Accu-Chek,  Roche,  Germany). 
The animals with fasting blood glucose level   14.0 
mmol/L  with  other  symptoms  of  diabetes  mellitus 
such as polyphagia, polydipsia, polyuria, and weight 
loss  were  considered  diabetic  and  included  in  the 
study. 
Treatment 
The animals were randomly divided into eight 
groups. Each group comprised five to seven rats. Dis-
tilled water, tualang honey, glibenclamide, and met-
formin were administered once daily by oral gavage. 
The treatment of animals began on the 3rd day after 
STZ injection and this was considered as 1st day of 
treatment. The animals were treated for 4 weeks as 
follows:  
 
  Group 1: Non-diabetic + Distilled water (0.5 ml) 
  Group  2:  Non-diabetic  +  Tualang  honey  (1.0 
g/kg body weight) 
  Group 3: Diabetic + Distilled water (0.5 ml) 
  Group  4:  Diabetic  +  Tualang  honey  (1.0  g/kg 
body weight) 
  Group 5: Diabetic + Glibenclamide (0.6 mg/kg 
body weight) 
  Group 6: Diabetic + Glibenclamide (0.6 mg/kg 
body weight) + Tualang honey (1.0 g/kg body Int. J. Biol. Sci. 2011, 7 
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weight) 
  Group 7: Diabetic + Metformin (100 mg/kg body 
weight) 
  Group 8: Diabetic + Metformin (100 mg/kg body 
weight) + Tualang honey (1.0 g/kg body weight) 
 
At the end of the treatment period, the animals 
were fasted for at least 16 hours and sacrificed by de-
capitation. Blood samples were collected in centrifuge 
tubes without anticoagulants and allowed to clot. The 
clotted blood was then centrifuged at 3000 x g for 20 
min. Serum was separated and then quickly stored at 
-80°C for biochemical analyses. 
Biochemical analyses 
 
Serum glucose was determined by  the glucose 
oxidase method as described by Barham and Trinder 
[14]. Serum concentrations of fructosamine were de-
termined by a colorimetric method (FRUC kit, Roche 
Diagnostics,  Mannheim,  Germany).  Serum  insulin 
was  determined  using  a  rat  insulin  enzyme-linked 
immunosorbent assay kit (Crystal Chem, Chicago, IL) 
with  rat  antibody.  Serum  high  density  lipoprotein 
cholesterol (HDL-C) was estimated by the method of 
Warnick [15]. Total cholesterol (TC) and triglycerides 
(TG) were estimated by the methods of Siedel et al. 
[16]  and  Foster  and  Dunn  [17],  respectively.  Low 
density lipoprotein cholesterol (LDL-C) and very low 
density lipoprotein cholesterol (VLDL-C) were calcu-
lated by Friedwald's formula [18]. Serum creatinine 
and urea were estimated using diagnostic kits based 
on the methods of Tomas [19]. Total bilirubin, albu-
min  and  globulin  levels  were  determined  using 
commercially available kits. 
Statistical analysis 
Statistical  analysis  was  carried  out  using  SPSS 
12.0.1. The data are expressed as mean ± SEM. Groups 
were compared by the Kruskal-Wallis H test followed 
by  Mann-Whitney  U  test  to  identify  significance  of 
difference between two groups.  P value < 0.05 was 
considered statistically significant.  
Results 
Body weight and food intake  
Figure  1  summarizes  the  results  of  the  body 
weight  and  food  intake  of  different  groups  of  rats. 
There  was  no  significant  difference  in  body  weight 
among the groups before the commencement of the 
study  (results  not  shown).  The  diabetic  control  rats 
had  significantly  (p  <  0.01)  reduced  body  weight 
compared to non-diabetic control rats. Tualang honey 
significantly (p < 0.05) improved body weight in dia-
betic rats compared to diabetic control rats. Neither 
glibenclamide nor metformin prevented weight loss 
in  diabetic  rats.  However,  the  diabetic  groups  that 
received glibenclamide or metformin in combination 
with  honey  showed  significant  (p  <  0.05)  improve-
ment  in  body  weight  compared  to  diabetic  control 
rats.  Besides,  the  diabetic  rats  that  received 
glibenclamide  in  combination  with  honey  showed 
significantly (p < 0.05) higher body weight compared 
to the diabetic rats that received glibenclamide alone. 
The diabetic control rats consumed significantly 
(p < 0.01) more pellets than the non-diabetic control 
rats. Although the amount of pellets consumed by the 
diabetic rats treated with glibenclamide, metformin, 
tualang  honey  or  their  combinations  was  less  com-
pared to that consumed by the diabetic control rats, 
there was no significant difference.  
Serum glucose, serum fructosamine and serum 
insulin 
Table 1 summarizes the results of serum glucose, 
serum  fructosamine  and  serum  insulin  in  different 
groups of animals at the end of the four-week treat-
ment period. The serum glucose concentrations of the 
diabetic control rats were significantly higher (22.4 ± 
1.0  mmol/L)  than  those  of  the  non-diabetic  control 
rats  (5.7  ±  0.3  mmol/L).  Treatment  with 
glibenclamide, metformin, or honey significantly de-
creased the glucose levels (13.9 ± 3.4, 13.2 ± 2.9 or 12.3 
± 3.1 mmol/L, respectively) in diabetic rats. Combi-
nation  of  glibenclamide  or  metformin  with  honey 
further reduced the glucose concentrations (8.8 ± 2.9 
or 9.9 ± 3.3 mmol/L, respectively) in diabetic rats. No 
significant effect of tualang honey in non-diabetic rats 
was observed (Table 1).  
The diabetic control rats showed significantly (p 
< 0.01) elevated levels of fructosamine (360.0 ± 15.6 
µmol/L) compared to non-diabetic control rats (145.3 
± 4.3 µmol/L). The diabetic rats that received tualang 
honey  showed  a  significant  (p  <  0.05)  decrease  in 
fructosamine  concentrations  (304.5  ±  10.1  µmol/L). 
On the contrary, administration of glibenclamide or 
metformin to diabetic rats did not produce any sig-
nificant difference on fructosamine levels compared 
to diabetic control rats. However, when glibenclamide 
or metformin was combined with tualang honey, the 
diabetic rats showed significantly (p < 0.05) reduced 
fructosamine levels compared to diabetic control rats 
(Table 1). 
The diabetic control rats had significantly (p < 
0.01) reduced insulin level (0.27 ± 0.01 ng/ml) com-
pared to non-diabetic rats (0.60 ± 0.12 ng/ml). Treat-
ment  of  diabetic  rats  with  tualang  honey, 
glibenclamide,  metformin  as  well  as  their  combina-
tions produced a significant increase in insulin levels Int. J. Biol. Sci. 2011, 7 
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compared to diabetic controls (Table 1). 
Serum creatinine, urea, bilirubin, albumin and 
albumin/globulin ratio  
Table 2 depicts the levels of creatinine, urea, bil-
irubin,  albumin  and  albumin/globulin  ratio  in  the 
serum of control and streptozotocin-induced diabetic 
rats. Significantly increased serum levels of creatinine, 
urea and bilirubin were observed in the diabetic con-
trol rats compared to non-diabetic rats. Serum levels 
of creatinine and bilirubin remained elevated in the 
diabetic rats treated with glibenclamide or metformin. 
However, glibenclamide or metformin combined with 
tualang honey significantly (p < 0.05) decreased se-
rum creatinine and bilirubin in diabetic rats compared 
to  diabetic  control  rats.  The  diabetic  control  rats 
showed significantly (p < 0.05) reduced albumin and 
albumin/globulin  compared  to  non-diabetic  control 
rats. The diabetic rats that received honey or metfor-
min showed significantly (p < 0.05) increased albumin 
and albumin/globulin compared to diabetic control 
rats. 
Serum triglycerides, total cholesterol, HDL 
cholesterol, LDL cholesterol and VLDL choles-
terol  
Table 3 shows the serum levels of triglycerides, 
total  cholesterol,  HDL  cholesterol,  LDL  cholesterol 
and  VLDL  cholesterol  of  control  and  streptozoto-
cin-induced  diabetic  rats.  Insignificantly  increased 
levels  of  TG  and  VLDL  cholesterol  with  no  much 
change in total cholesterol, HDL cholesterol and LDL 
cholesterol  levels  were  observed  in  diabetic  control 
rats compared to non-diabetic rats. Administration of 
tualang  honey,  glibenclamide  or  metformin  signifi-
cantly (p < 0.05) decreased the levels of TG and VLDL 
cholesterol in diabetic rats compared to diabetic con-
trol  rats.  Besides,  combination  of  glibenclamide  or 
metformin  with  tualang  honey  further  reduced  the 
levels  of  TG  and  VLDL  cholesterol  in  diabetic  rats. 
Glibenclamide  alone  as  well  as  combination  of 
glibenclamide or metformin with tualang honey sig-
nificantly decreased TC in diabetic rats. 
 
Figure 1. Effects of tualang honey, glibenclamide, metformin or their combinations on (a) body weight and (b) food intake 
in streptozotocin-induced diabetic rats. NC (Non-diabetic control); NH (Non-diabetic + Honey); DC (Diabetic control); 
DH (Diabetic + Honey); DG (Diabetic + Glibenciamide); DGH (Diabetic + Glibenciamide + Honey); DM (Diabetic + 
Metformin); DMH (Diabetic + Metformin + Honey). Data are expressed as mean ± SEM. Each group consisted of five to 
seven animals. Values are statistically significant at * p < 0.05, ** p < 0.01 compared to NC; † p < 0.05 compared to DC; # 
p < 0.05 compared to DG. Int. J. Biol. Sci. 2011, 7 
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Table 1. Effects of tualang honey, glibenclamide, metformin or their combinations on serum glucose, serum fructosamine 
and serum insulin in streptozotocin-induced diabetic rats. 
Group   Serum glucose 
(mmol/L) 
Serum fructosamine  
(µmol/L) 
Serum insulin 
(ng/ml) 
 Non-diabetic control  5.7 ± 0.3  145.3 ± 4.3  0.60 ± 0.12  
 Non-diabetic + Honey  5.6 ± 0.1  149.2 ± 2.6  0.57 ± 0.13 
 Diabetic control  22.4 ± 1.0**  360.0 ± 15.6**  0.27 ± 0.01**  
 Diabetic + Honey  12.3 ± 3.1†  304.5 ± 10.1**,†  0.41 ± 0.06†† 
 Diabetic + Glibenclamide  13.9 ± 3.4*,†  330.0 ± 29.9**  0.39 ± 0.02†† 
 Diabetic + Glibenclamide + Honey  8.8 ± 2.9†  301.3 ± 19.5**,†  0.32 ± 0.02† 
 Diabetic + Metformin  13.2 ± 2.9†  314.6 ± 17.9**  0.36 ± 0.03† 
 Diabetic + Metformin + Honey 
 
9.9 ± 3.3† 
 
285.8 ± 22.6**,† 
 
0.33 ± 0.02*,†  
 
Data are expressed as mean ± SEM. Each group consisted of five to seven animals.  
Values are statistically significant at * p < 0.05, ** p < 0.01 compared to non-diabetic control;  
† p < 0.05, †† p < 0.01 compared to diabetic control. 
 
Table 2. Effects of tualang honey, glibenclamide, metformin or their combinations on creatinine, urea, bilirubin, albumin and 
albumin/globulin ratio in the serum of streptozotocin-induced diabetic rats. 
Group  Creatinine 
(µmol/L) 
Urea  
(mmol/L) 
Bilirubin  
(µmol/L) 
Albumin 
 (g/L) 
Albumin/ Globulin 
Non-diabetic control  27.8 ± 3.3  5.2 ± 0.3  1.50 ± 0.22  30.3 ± 1.2  0.80 ± 0.03  
Non-diabetic + Honey  34.8 ± 3.3  5.9 ± 0.4  1.60 ± 0.40  31.2 ± 0.4  0.88 ± 0.02  
Diabetic control  37.0 ± 1.4*  20.3 ± 2.4**  3.33 ± 0.42**  23.0 ± 1.8**  0.66 ± 0.03*  
Diabetic + Honey  25.6 ± 4.0  17.5 ± 2.6**  2.00 ± 0.37†  27.6 ± 0.9†  0.81 ± 0.04†  
Diabetic + Glibenclamide  32.0 ± 4.7  17.7 ± 1.1**  2.60 ± 0.69  27.8 ± 1.9  0.71 ± 0.06  
Diabetic + Glibenclamide + 
Honey 
26.7 ± 3.9†  15.5 ± 1.5**  1.67 ± 0.42†  27.6 ± 1.6  0.73 ± 0.05  
Diabetic + Metformin  32.7 ± 2.9  19.0 ± 2.4**  2.29 ± 0.52  28.6 ± 1.4†  0.80 ± 0.03†  
Diabetic + Metformin + 
Honey 
 
25.2 ± 3.8† 
 
20.0 ± 1.2** 
 
1.60 ± 0.24† 
 
25.7 ± 1.8 
 
0.82 ± 0.03†  
 
Data are expressed as mean ± SEM. Each group consisted of five to seven animals. Values are statistically significant at * p < 0.05, ** p < 0.01 
compared to non-diabetic control; † p < 0.05 compared to diabetic control. 
 
Table 3. Effects of tualang honey, glibenclamide, metformin or their combinations on triglycerides (TG), total cholesterol 
(TC), high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and very low density lipoprotein 
(VLDL) cholesterol in the serum of streptozotocin-induced diabetic rats. 
Group 
 
 
TG 
(mg/dL) 
 
TC 
(mg/dL) 
 
HDL-C 
(mg/dL) 
 
LDL-C 
(mg/dL) 
 
VLDL-C 
(mg/dL) 
 
Non-diabetic control  0.44 ± 0.04  1.50 ± 0.15  0.81 ± 0.08  0.42 ± 0.07  0.20 ± 0.02  
Non-diabetic + Honey  0.51 ± 0.02  1.60 ± 0.11  0.88 ± 0.03  0.49 ± 0.08  0.23 ± 0.01 
Diabetic control  0.71 ± 0.21  1.52 ± 0.09  0.75 ± 0.09  0.39 ± 0.04  0.32 ± 0.10  
Diabetic + Honey  0.25 ± 0.04*,†  1.42 ± 0.12  0.89 ± 0.09†  0.38 ± 0.05  0.14 ± 0.03† 
Diabetic + Glibenclamide  0.30 ± 0.08†  1.07 ± 0.07*,††  0.64 ± 0.09  0.29 ± 0.03  0.14 ± 0.04† 
Diabetic + Glibenclamide + Honey  0.21 ± 0.04**,†  1.14 ± 0.08†  0.82 ± 0.12  0.41 ± 0.03  0.10 ± 0.02**,† 
Diabetic + Metformin  0.38 ± 0.19*,†  1.38 ± 0.16  0.87 ± 0.09  0.34 ± 0.03  0.17 ± 0.08*,† 
Diabetic + Metformin + Honey 
 
0.17 ± 0.02**,†† 
 
0.89 ± 0.15*,† 
 
0.67 ± 0.11 
 
0.24 ± 0.04† 
 
0.07 ± 0.01**,† 
 
Data are expressed as mean ± SEM. Each group consisted of five to seven animals. Values are statistically significant at * p < 0.05, ** p < 0.01 
compared to non-diabetic control; † p < 0.05, †† p < 0.01 compared to diabetic control. 
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Discussion 
In STZ-induced diabetic rats, insulin deficiency 
or  hypoinsulinemia  develops  as  a  consequence  of 
irreversible destruction of the β-cells of the pancreas 
resulting in hyperglycemia [20]. Glibenclamide, met-
formin or honey significantly reduced blood glucose 
concentrations in our study which is similar to find-
ings from previous studies [12; 21-23]. However, the 
hypoglycemic  effect  of  tualang  honey  was  not  ob-
served in the non-diabetic rats similar to our previous 
finding [12-13]. This indicates that similar to what has 
been previously reported for metformin [24], the hy-
poglycemic effect of honey might also be glucose de-
pendent and thus possessing euglycemic rather than 
hypoglycemic effect in non-diabetic rats. 
 
The mechanisms of action of glibenclamide and 
metformin are well documented [25-26]. On the con-
trary, it is still unknown how honey mediates its hy-
poglycemic  effect  in  diabetes.  However,  based  on 
current literature, one may suggest that tualang honey 
might possibly exert its hypoglycemic effect through 
fructose  which  is  the  predominant  constituent  [27]. 
Fructose neither increases plasma glucose nor its me-
tabolism requires insulin secretion [28]. Dietary fruc-
tose is known to activate glucokinase which is a key 
enzyme  involved  in  the  intracellular  metabolism  of 
glucose. It catalyzes the conversion of glucose to glu-
cose-6-phosphate  thereby  decreasing  blood  glucose 
[29].  A  previous  study  also  reported  that  fructose 
stimulated insulin secretion from an isolated pancreas 
[30].  However,  stronger  evidence  in  support  of  the 
role of fructose in mediating hypoglycemic effect of 
honey is provided by Curry and his colleagues [31]. 
They found that in rat pancreas preparations, there 
was no insulin response to fructose when very low or 
no concentrations of glucose were present in the me-
dium. In contrast, it was observed that with higher 
glucose  concentrations,  insulin  response  to  fructose 
was elicited [31]. These findings seem to corroborate 
ours  where  we  found  that  tualang  honey  showed 
hypoglycemic effect in diabetic rats but did not pro-
duce such an effect in non-diabetic rats.  
Furthermore, honey is reported to have a lower 
glycemic  index  compared  to  many  other  carbohy-
drates [32]. With regards to the compositions of tua-
lang honey [fructose (29.6 %), glucose (30.0 %), fruc-
tose/glucose ratio (0.99)], the nearly 1:1 ratio of fruc-
tose to glucose might indicate its uniqueness in com-
parison to some types of honey which have 1:2 ratio of 
fructose to glucose [33]. Besides, unlike other common 
kinds of honey which are produced by Apis mellifera 
[27], tualang honey is produced by Apis dorsata [13]. 
Moreover, tualang honey is of polyfloral origin com-
pared to others which are from monofloral sources. 
So, these and other properties may distinguish tua-
lang honey from other types of honey. In addition to 
fructose  and  glucose,  honey  is  known  to  contain 
fructooligosaccharides which provide prebiotic bene-
fits to the intestinal microflora such as bifidobacteria 
and lactobacilli, which are probiotics [34-36]. Since the 
gastrointestinal microflora is now identified to play a 
key role in health and disease, honey may help im-
prove gut health in diabetes and perhaps impact on 
glucose  management  by  additional  mechanisms 
which need to be explored. 
Honey also contains elements such as zinc, sele-
nium, copper, calcium, potassium, chromium,  man-
ganese, etc [27]. Some of these minerals are reported 
to play vital roles in the maintenance of normal glu-
cose tolerance and insulin secretion from the pancre-
atic β-cells [37-38]. Other ions such as copper and zinc 
are also known to be involved in glucose and insulin 
metabolism [39-40]. Even though the amounts of these 
minerals in honey may be small, it is worthwhile to 
note  that  these  trace  elements  are  not  actually  re-
quired in large quantities. Daily supplementation of 
the diabetic rats with tualang honey for four weeks 
might attain sufficient concentrations of these miner-
als to elicit pharmacological responses which syner-
gistically contribute to the hypoglycemic effect. Fur-
thermore,  improved  secretion  of  insulin  from  the 
pancreas  (possibly  due  to  protective  effect  on  beta 
cells) might contribute to the hypoglycemic effect of 
tualang honey.  
Tight glycemic control is now recognized as one 
of  the  main  therapeutic  goals  to  prevent  diabetic 
complications [1, 2]. HbA1c is commonly used as an 
indicator of glycemic control [41]. Findings from the 
DCCT  showed  that  there  is  a  relationship  between 
HbA1c and glycemic control [1]. Since HbA1c measures 
blood glucose control over a period of eight to twelve 
weeks, it will not be a valid test in this study which 
lasted for four weeks. Therefore, we measured fruc-
tosamine which reflects a two to three week period of 
glycemic control prior to blood testing. Fructosamine 
is a stable product formed as result of protein modi-
fication by glucose and its serum level is reported to 
increase in diabetes [42]. Fructosamine can undergo 
oxidative  cleavage  leading  to  the  formation  of  ad-
vanced  glycation  end  products  (AGEs),  which  are 
implicated  in  long-term  complications  of  diabetes 
mellitus  [42].  We  observed  that  fructosamine  was 
significantly elevated in the serum of the diabetic rats 
similar  to  what  was  previously  reported  [43].  Our 
results further showed that unlike honey which sig-
nificantly  decreased  fructosamine  levels,  neither 
glibenclamide  nor  metformin  reduced  the  elevated Int. J. Biol. Sci. 2011, 7 
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levels of fructosamine. A previous study also found 
that  glibenclamide  did  not  reduce  fructosamine  in 
diabetic rats [43].  
Surprisingly, significantly reduced fructosamine 
levels were observed when glibenclamide or metfor-
min  was  combined  with  tualang  honey.  Therefore, 
this suggests that these hypoglycemic drugs in com-
bination with tualang honey produced better glyce-
mic control. It is still unclear how tualang honey de-
creased  fructosamine  concentration.  However,  this 
may be linked to the previously reported antioxidant 
effect of tualang honey [12-13]. Previous studies have 
reported that antioxidants such as vitamins C and E 
reduce HbA1c values by inhibiting protein glycation 
[44-45].  Besides,  Gly-13-C,  an  antioxidant  was  also 
reported to reduce fructosamine in diabetic rats [43]. 
The  same  groups  of  diabetic  animals  that  showed 
significantly reduced fructosamine levels also exhib-
ited  much  lower  glucose  concentrations.  Therefore, 
based  on  these  results,  one  may  suggest  that  the 
combination  of  hypoglycemic  drugs  with  honey  or 
possibly other antioxidants may reduce the formation 
and/or the deleterious effects of advanced glycation 
endproducts  (AGEs)  which  may  perhaps  delay  the 
development  and  progression  of  diabetic  complica-
tions. 
Induction of diabetes by STZ resulted in loss of 
body weight in the diabetic control rats. Our results 
showed  that  neither  glibenclamide  nor  metformin 
prevented weight loss. On the other hand, these drugs 
in  combination  with  honey  reduced  weight  loss  in 
diabetic  rats.  The  mechanisms  by  which  honey  im-
proves body weight are unclear. Insulin is reported to 
have anabolic effect on protein metabolism by stimu-
lating protein synthesis and retarding protein degra-
dation [46]. Although tualang honey increased serum 
insulin, considering the levels of insulin in the dia-
betic rats that received glibenclamide or metformin in 
combination with honey, the additional effect of tua-
lang honey on body weight in these rats could not be 
attributed to insulin. Perhaps, the fructose constituent 
of tualang honey [47] or improved glycemic control 
due to tualang honey might contribute to weight gain.  
 
Increased  serum  levels  of  urea  and  creatinine, 
indicators of impaired renal function [48], were ob-
served  in  the  diabetic  control  rats.  Their  levels  re-
mained elevated in the diabetic rats treated with tua-
lang  honey,  glibenclamide  or  metformin.  However, 
glibenclamide  or  metformin  in  combination  with 
honey significantly decreased serum creatinine. This 
suggests  that  combination  of  hypoglycemic  drugs 
with  tualang  honey  may  have  beneficial  effect  in 
preventing renal damage, perhaps through improved 
glycemic control and amelioration of oxidative stress 
as  previously  reported  [12-13].  Microalbuminuria  is 
one  of  the  clinical  manifestations  of  diabetic 
nephropathy.  Albuminuria,  which  may  be  due  to 
leakage  of  albumin  by  damaged  glomerular  mem-
brane,  is  reported  to  develop  in  untreated  diabetes 
mellitus [48]. Reduced levels of serum albumin and 
albumin/globulin in the diabetic rats might indicate 
renal leakage. Treatment with tualang honey or met-
formin  increased  serum  albumin  and  albu-
min/globulin ratio. These data suggest that tualang 
honey may help in the repair of renal damage. 
  
Diabetes  is  characterized  by  insulin  deficiency 
which  causes  increased  lipolysis  in  adipose  tissues 
and increased entry of free fatty acids (FFA) to the 
liver  [49].  Increased  FFA  and  insulin  independent 
glucose  uptake  in  the  liver  is  reported  to  stimulate 
triglyceride synthesis [50]. This increased synthesis of 
triglycerides tends to reduce protein content of lipo-
proteins, especially in VLDL and LDL while the tri-
glyceride content increases [51]. This alteration in the 
protein  and  triglyceride  compositions  results  in  re-
duced uptake of these lipoproteins by their receptors 
[51]. As a result, dyslipidemia related to abnormalities 
in  serum  lipoproteins  is  an  impending  atherogenic 
risk factor in diabetes [52]. In this study, the diabetic 
control rats showed insignificant increases in TG and 
VLDL  levels  while  no  significant  change  was  ob-
served in total cholesterol, HDL cholesterol and LDL 
cholesterol levels. Our findings are similar to those of 
Bin and his colleagues who also found insignificant 
lipid  abnormalities  in  diabetic  rats  [53].  However, 
other  researchers  did  report  significant  changes  in 
lipid abnormalities [49]. The decreased levels of TG 
and  VLDL  cholesterol  in  diabetic  rats  that  received 
glibenclamide or metformin seem to corroborate pre-
vious  findings  that  these  drugs  do  ameliorate 
dyslipidemia  [21,  22,  25-26].  Besides,  significantly 
lower levels of VLDL cholesterol and TG observed in 
diabetic  rats  that  received  a  combination  of 
glibenclamide or metformin with tualang honey fur-
ther demonstrate that tualang honey combined with 
these hypoglycemic agents produces synergistic effect 
in reducing VLDL cholesterol and TG in diabetic rats.  
In conclusion, these results indicate that addition 
of  tualang  honey  to  glibenclamide  or  metformin  in 
STZ-induced  diabetic  rats  helps  to  achieve  serum 
glucose  and  fructosamine  levels  much  lower  than 
those  achieved  with  glibenclamide  or  metformin 
alone. Honey as an adjunct to glibenclamide or met-
formin  leads  to  an  improved  glycemic  control  and 
some additional metabolic benefits not achieved with 
either glibenclamide or metformin alone. This study 
seems to suggest that the combination of honey with Int. J. Biol. Sci. 2011, 7 
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oral hypoglycemic agents may be a valuable adjuvant 
therapy to achieve and/or maintain glycemic control 
and  possibly  reduce  or  delay  the  onset  of  diabetic 
complications. A similar study in human subjects is 
desirable to determine if these results can be appro-
priately extrapolated to human diabetes. 
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